Australian Clinical Labs Ltd (acl) Logo

Australian Clinical Labs Ltd (ACL)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

ACL Chart

Snapshot

ACL's Principal Activity is the provision of pathology diagnostic services

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) +56.85%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 292 of 2,408
Sector Rank 13 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies NAN / IMU / TLX
EPS $0.397
DPS $0.12
Book Value Per Share $0.41

Broker Consensus

ACL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Australian Clinical Labs Limited (ACL) is a private provider of pathology services in Australia. ACL's mission is to combine talented people, medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives. It is servicing over 90 private and public hospitals.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Clayton VIC 3168
Website www.clinicallabs.com.au
Registry Link Market Services
Auditor Pitcher Partners
Date Listed 14 May 2021

Upcoming Calendar (Forecasted)

Date Event
25/08/2022 Report (Prelim)
23/09/2022 Report (Annual)
23/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
25/03/2022 $0.12 100% $0.1714 Interim 21/04/2022

See Upcoming Dividends for all ASX companies.

Key Data
DPS(TTM) $0.12
Gross DPS(TTM) $0.1714
Dividend yield
Gross yield
Payout Ratio 0%
DRP Yes
DRP Features -

Directors & Management

Directors & Management

Name Title Since Bio
Dr Michael Philip Stanford Non-Executive Director Apr 2021

Dr Michael Philip Stanford

Non-Executive Director

Mr Stanford has over 25 years of Non-Executive Director experience across a range of industries including healthcare services, diagnostics, biotech, pharmaceutical, property, aged care and higher education. Mr Stanford is the current Chair of Diabetes Australia, an Independent Non-Executive Director of NorthWest Healthcare Property Management Limited and Nucleus Network Limited, and a Senior Advisor at Medibank Private Limited. Mr Stanford's former roles include Non-Executive Director for ACL between 2016 and 2019, Healthscope Limited, Virtus Health Limited, and Deputy Chancellor of Curtin University. He was in Group Chief Executive Officer roles for 23 years including 16 years at St John of God Health Care. Mr Stanford has also received a Member of the Order of Australia for his service to the health sector, to tertiary education and in the community of Western Australia.

Dr Leanne Rowe Non-Executive Director Apr 2021

Dr Leanne Rowe

Non-Executive Director

Dr Rowe has been a Non-Executive Director of ACL since 28 April 2021. Dr Rowe is a clinical professor and medical practitioner with over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Dr Rowe is currently Chair of Nexus Hospitals and a Non-Executive Director of Japara Healthcare Limited, Doctor Care Anywhere Group PLC, the Medical Indemnity Protection Society and MIPS Insurance. Previously she was Chair of the Royal Australian College of General Practitioners and a Non-Executive Director of Medibank Private, I-MED Radiology Network, GMHBA, Australian Health Management, Barwon Health and Beyond Blue.

Mr Andrew Mark Rendle Dutton Non-Executive Director Apr 2021

Mr Andrew Mark Rendle Dutton

Non-Executive Director

Mr Dutton has been a Non-Executive Director of ACL since 28 April 2021. Mr Dutton has 30 years of management, business development and technology experience across Australia, Asia and Europe. Mr Dutton is the current Chair of Land Registry Services and was recently an Advisor to FinancialForce APJ. He has had Chief Executive Officer and Board experience globally and within Australia. Mr Dutton's former roles include Chair of NVOI Pty Ltd and SAI Global Pty Ltd; Chief Executive Officer at Land Registry Services and Integrated Research Limited; Managing Director of the Asia Pacific/Japan region for VMware Inc.; and senior executive positions at IBM, Computer Associates, BEA Systems Inc., Lend Lease and Norwich Union Financial Services Group including roles as CFO, CMO, CRO and Divisional Heads. At IBM, Mr Dutton was elected to the Worldwide Senior Leadership Team.

Mr Mark Haberlin Non-Executive Director Apr 2021

Mr Mark Haberlin

Non-Executive Director

Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mr Haberlin is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Mr Haberlin is also an Independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Limited. Previously, Mr Haberlin was the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific.

Mr Michael Thomas Alscher Non-Executive Chairman,Non-Executive Director Dec 2020

Mr Michael Thomas Alscher

Non-Executive Chairman,Non-Executive Director

Mr Alscher was appointed Chair of ACL's predecessor corporate vehicle Clinical Laboratories Pty Ltd in 2015 following its acquisition by Crescent Capital Partners in 2015. Mr Alscher was appointed a Director of ACL on 19 December 2020 and Chair of ACL as part of the IPO process on 19 December 2020. Mr Alscher is the Managing Partner and founder of Crescent, a leading Australian private equity investment firm, specialising in high growth companies and certain industry sectors such as healthcare. Mr Alscher is the current Chair of Cardno Limited, National Dental Care Limited, National Home Doctor Service Pty Ltd and is a Non-Executive Director of Clearview Wealth Limited. Mr Alscher's former director roles include Chair of Cover-More Group Limited, LifeHealthcare Group Limited and Director of Metro Performance Glass Limited. Prior to founding Crescent in 2000, Mr Alscher was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles.

Mr Nathanial Jonothan Thomson Non-Executive Director Dec 2020

Mr Nathanial Jonothan Thomson

Non-Executive Director

Mr Thomson has been a Non-Executive Director of ACL's predecessor corporate vehicle, Clinical Laboratories Pty Ltd, since April 2018. Mr Thomson was appointed a Non-Executive Director of ACL on 19 December 2020. Mr Thomson is a Partner at Crescent, a leading Australian private equity investment firm. Mr Thomson has over 20 years of experience in strategy consulting, private equity and investment banking. He has consulting experience from his prior role at McKinsey & Co. Mr Thomson is a current Director of Cardno Limited, National Dental Care Limited, Clearview Wealth Limited and National Home Doctor Service Pty Ltd. Mr Thomson's former director roles include Deputy Chair of Cover-More Group Limited and a Non-Executive Director of Metro Performance Glass Limited.

Ms Melinda Leigh McGrath Chief Executive Officer,Executive Director Dec 2020

Ms Melinda Leigh McGrath

Chief Executive Officer,Executive Director

Ms McGrath has been the Chief Executive Officer and Executive Director of ACL's predecessor corporate vehicle, Clinical Laboratories Pty Ltd since 2015. Ms McGrath was appointed an Executive Director of ACL on 19 December 2020. Ms McGrath has more than 30 years' experience in healthcare with over 20 years of experience in chief executive roles and over 13 years of experience in pathology CEO roles. Ms McGrath has played a lead role in the organisation's transformation, building ACL's scale and operational performance improvement over the past six years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology and SunDoctors. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Ms McGrath was Chief Executive Officer of QML Pathology (part of Healius) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Ms McGrath held various chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Ms McGrath has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services; and a superannuation fund, UC Super.

Ms Eleanor Padman Company Secretary N/A
James Davison Chief Financial Officer N/A

Director Transactions

ACL directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
21/04/22 Michael Alscher Issued 5,928 $5.06 $29,995 Dividend Reinvestment Plan (DRP)
21/04/22 Andrew Dutton Issued 1,897 $5.06 $9,598 Dividend Reinvestment Plan (DRP)
21/04/22 Melinda McGrath Issued 15,841 $5.06 $80,155 Dividend Reinvestment Plan (DRP)
21/04/22 Melinda McGrath Issued 50,359 $5.06 $254,816 Dividend Reinvestment Plan (DRP)
25/02/22 Michael Stanford Buy +8,000 $4.62 $36,960 On-market trade
22/11/21 Mark Haberlin Buy +22,500 $4.399 $98,988 On-market trade
25/05/21 Melinda McGrath Issued 247,252 $3.64 $899,997 Issue of securities

Director Interests

The current holdings of ACL directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Melinda McGrath 21/04/2022 2,173,867 683,806 N/A N/A
Andrew Dutton 21/04/2022 N/A 81,897 N/A N/A
Michael Alscher 21/04/2022 N/A 255,928 N/A N/A
Michael Stanford 25/02/2022 20,000 18,000 N/A N/A
Mark Haberlin 22/11/2021 N/A 47,500 N/A N/A
Leanne Rowe 30/06/2021 N/A 37,500 N/A N/A
Nathanial Thomson 19/12/2020 0 N/A N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Sep 8, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Crescent Capital Partners 39,270,974 19.46%
HSBC Custody Nominees (Australia) Limited 27,912,181 13.83%
Citicorp Nominees Pty Limited 24,293,812 12.04%
National Nominees Limited 18,924,054 9.38%
Instanz Nominees Pty Ltd 14,036,045 6.95%
CCP Trusco 1 Pty Ltd 13,158,261 6.52%
CCP Trusco 5 Pty Ltd 6,207,125 3.08%
CCP Trusco 2 Pty Ltd 5,765,804 2.86%
CCP Trusco 4 Pty Ltd 5,533,472 2.74%
JP Morgan Nominees Australia Pty Limited 3,624,902 1.80%
BNP Paribas Noms Pty Ltd 3,544,378 1.76%
Perpetual Corporate Trust Ltd 3,074,742 1.52%
Perpetual Corporate Trust Ltd I 2,635,495 1.31%
Brispot Nominees Pty Ltd 2,541,938 1.26%
Melinda McGrath 2,123,508 1.05%
Hsbc Custody Nominees (Australia) Limited I 2,031,155 1.01%
Morgan Stanley Australia Securities (Nominee) Pty Limited 980,557 0.49%
CS Fourth Nominees Pty Limited 911,576 0.45%
Anthony Landgren 838,211 0.42%
UBS Nominees Pty Ltd 830,226 0.41%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 1,007 1,172 403 274 48 2,904

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Crescent Capital Partners Management Pty Limited 14/09/2021 89,681,918 44.43
Yarra Funds Management Limited 14/04/2022 10,108,181 5.01
Ethical Partners Funds Management Pty Ltd 24/11/2021 19,558,112 9.69

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
14-04-22 Yarra Funds Management Limited 10,108,181 -- 5.01
24-11-21 Ethical Partners Funds Management Pty Ltd 2,159,693 8.62 9.69
02-07-21 Ethical Partners Funds Management Pty Ltd 5,800,142 5.75 8.62
19-05-21 Ethical Partners Funds Management Pty Ltd 11,598,277 -- 5.75

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
19-05-21 ACL SaleCo Limited 49,346,290 33.5 --
18-05-21 Crescent Capital Partners Management Pty Limited 44,610,563 91.2 44.4

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $3.37 30 June
ACL Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.